DMD and Duchenne muscular dystrophy: The aim of this treatment is to address the underlying cause of DMD through targeted expression of SRP-9001 dystrophin, a shortened dystrophin protein that retains the key functional domains of the wild-type protein, in skeletal and cardiac muscle (Mendell et al., 2020).